🔗 Share this article

Given that the United States continues making unprecedented changes to its vaccine schedules, one figure has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccines in the pandemic and has zeroed in on alleged deaths following Covid vaccination in her recent position at the FDA.

Scheduled Overhauls to Childhood Vaccine Schedule

Health officials were set to reveal sweeping revisions to the pediatric immunization program in December, bringing the US with the Danish national calendar, sources say – a significant shift that would place the US out of step with many the global community with no evidence for benefit. This reveal has been pushed back until the coming year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to present at the gathering. She was recently named interim head of the FDA’s CDER, the fifth person to head the center this calendar year.

A Shift at the Agency

This interim role may indicate a closer partnership between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a greater focus upon rolling back already-approved vaccines at the FDA.

Høeg has frequently advocated for halting some childhood immunization guidelines in the US so as to align more similar to Denmark, a country with nationalized medicine and a population roughly the population of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccination policy – usually the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Background

The appointee has no apparent experience in medication creation, regulation or management, which has been typical for past directors of the CBER. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for leading the CDER, stated Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a major agency. She has no expertise in industry regulation.”

Past directors of the center would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that prior appointees who led CBER have had.”

The drug center has an enormous workload at the agency, she pointed out.

“The public just pays attention on the novel medication approvals, but the generic drug division authorizes numerous generic drugs. There is also a biologic copycat branch, non-prescription drug unit and more, and every single one must be supervised,” Dr. Woodcock noted. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a significant leadership component to the role, which manages over 5,000 employees. “It’s a huge management job, if you do it right,” she concluded.

Agency Reaction and Contentious Policies

Regarding inquiries about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among agency officials on vaccines, a representative said that the “inquiries rely on incorrect premises”.

“Her resume aligns with the functions of her role,” the representative explained, noting the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s recently launched expedited review system, a controversial one-day drug-approval program that apparently worried her predecessors. “By what process are these medications being selected for this expedited pathway? Who is making the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the agency right now.”

In general, he remarked, “the agency looks to be trending towards laxer rules of most medications, except for immunizations.”

Established Track Record on Immunizations

With vaccines, Dr. Høeg has a more established, if troubling, past, some experts observe. She released a study using unconfirmed crowd-sourced reports to estimate the frequency of heart inflammation following Covid vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are riskier than they are.

Among her “policy goals” for the new administration featured altering regulations for recently developed shots and halting “optional” immunizations, she stated post-election on a audio program. At the FDA, Høeg has reportedly floated the idea of preventing teenage boys from getting COVID-19 vaccines.

“She is an thorough dogmatist who commences with her conclusions and reverse-engineers to accommodate the evidence in a extremely disingenuous, fraudulent manner,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|